Desvenlafaxine as a Potential First-Line Treatment for Major Depressive Disorder: A Comprehensive Review and Consensus-Based Clinical Perspective on Efficacy, Safety and Patient Selection Profiles

Major depressive disorder is a leading cause of disability worldwide, with significant challenges in treatment response, adherence and functional recovery. Despite the availability of numerous antidepressants, a substantial proportion of patients fail to achieve remission with initial therapy, underscoring the need for effective first-line treatment options. Desvenlafaxine, a serotonin-noradrenaline reuptake inhibitor, has demonstrated efficacy and safety in major depressive disorder, while its pharmacokinetic properties result in minimal drug–drug interactions. This narrative review evaluates clinical evidence supporting the use of desvenlafaxine as a first-line treatment and examines patient subgroups that may benefit most from this antidepressant. A comprehensive literature review was conducted to evaluate the evidence on desvenlafaxine in the treatment of major depressive disorder. This was supplemented by clinical insights discussed during a virtual advisory board meeting held on 16 December, 2024, attended by the authors—psychiatrists from Italy, Germany, Spain, Ireland and Portugal—together with representatives from Neuraxpharm, who market desvenlafaxine. The available evidence suggests that desvenlafaxine offers early symptom relief, sustained efficacy across diverse major depressive disorder symptom clusters, and benefits for patients with anhedonia, fatigue, cognitive dysfunction and functional impairment. Its tolerability and safety profile, including a lower risk of weight gain and drug–drug interactions, contributes to its ease of use and improved adherence. Based on the authors’ clinical consensus, desvenlafaxine may be particularly suitable for working-age adults, perimenopausal and menopausal women, those with general medical comorbidities or polypharmacy concerns, and individuals requiring an antidepressant with a broad mechanism of action. In addition, its predictable pharmacokinetics make it a practical choice in primary care settings. While most current guidelines typically recommend selective serotonin reuptake inhibitors as first-line treatment, the favourable tolerability profile and efficacy of desvenlafaxine across diverse symptom clusters may support its consideration as a first-line option in select patient populations. Depression is a common mental health condition that can seriously impact on a person’s daily life, work and relationships. Many people with depression struggle to find an effective treatment, and even when they do, side effects such as weight gain or sexual dysfunction can make it difficult to continue taking medication. Desvenlafaxine is a type of antidepressant known as a serotonin-noradrenaline reuptake inhibitor. It works by targeting two important chemical pathways in the brain—serotonin and noradrenaline—which help improve depressive symptoms. This article reviews the scientific evidence on how well desvenlafaxine works, how safe it is, and which patients may benefit most from it as a first-choice treatment for depression. This article is based on a review of the existing published literature and clinical insights from a meeting of psychiatry experts from different countries. The findings suggest that desvenlafaxine can provide relief from symptoms of depression early in treatment, is effective for patients with low energy, difficulty concentrating or lack of motivation, and is less likely than some other antidepressants to cause weight gain. Based on the available evidence and the experts’ experience, desvenlafaxine may be particularly useful for patients who take multiple medications as it has a lower risk of interactions with other drugs. While not suitable for everyone, desvenlafaxine may be a valuable option for many people with depression, particularly those who need quick symptom relief, actively employed adults, perimenopausal women, individuals with comorbid physical health conditions, and those who struggle with fatigue and cognitive problems.